IL-17, IL-23 and IL-12/23 biologics on HealthSpring Assurance Rx (S5617-123)
Stelara and its biosimilars, Skyrizi, Tremfya, Cosentyx and Taltz, for psoriasis, psoriatic arthritis and Crohn's, checked against this plan's 2026 formulary (its list of covered drugs).
- Plan type
- Stand-alone drug plan (PDP), Iowa + 6 more
- Premium
- $125.90/month
- Deductible
- $615.00
6 of 9 IL-17 and IL-23 biologics are covered on this plan. All 6 require prior authorization.
3 aren't on the formulary, including Wezlana and Taltz.
- from $1,212.25Tier 5
- from $1,212.25Tier 5
- from $451.26Tier 3
- from $2,259.03Tier 5
- from $3,526.44Tier 5
- from $5,835.12Tier 5
Not on the formulary
Wezlana, Taltz, Bimzelx
Patient cost for a 30-day supply at a preferred retail pharmacy, after the $615.00 deductible where it applies. Where the plan charges a percentage (coinsurance), the dollar figure is that share of the plan's negotiated price; "from" means other strengths cost more. Data from the CMS 2026 Part D formulary and pricing files.